Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2012

 

 

CELGENE CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-34912   22-2711928

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

86 Morris Avenue, Summit,

New Jersey

  07901
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (908) 673-9000

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

(e) At the annual meeting of stockholders (the “Annual Meeting”) of Celgene Corporation (the “Company”) held on June 13, 2012, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s 2008 Stock Incentive Plan (the “Plan”) to, among other things:

 

   

Adopt an aggregate share reserve of 95,981,641 shares of our Common Stock. This number includes our current share reserve of 81,981,641 shares of our Common Stock and 14,000,000 additional new shares of our Common Stock.

 

   

In connection with the increase in the aggregate share reserve, the “fungible” share limit, which limits the number of “full-value awards” (e.g., restricted stock and RSUs) that may be granted under the Plan by counting shares granted pursuant to such awards as multiple shares against the aggregate share reserve, will be changed from 1.6 shares for every share granted to 2.1 shares for every share granted.

 

   

Extend the term of the Plan through April 18, 2022.

In addition to the foregoing, our stockholders reapproved the Section 162(m) performance goals under the Plan so that certain incentive awards granted under the Plan to executive officers of the Company may qualify as exempt performance-based compensation under Section 162(m) of the Internal Revenue Code.

The foregoing is a brief summary of the principal provisions of the amendments to the Plan and does not purport to be complete and is qualified in its entirety by reference to the full text of the Plan, as amended by the Amendment, which Amendment is attached as Exhibit 10.1 and incorporated herein by reference.

 

ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

(a) The annual meeting of stockholders of the Company was held on June 13, 2012.

(b) Stockholders voted on the matters set forth below:

Proposal 1. Election of Directors:

 

     For      Against      Withheld      Broker Non-Votes  

Robert J. Hugin

     307,901,783         N/A         8,956,466         50,102,750   

Richard W. Barker, D.Phil.

     314,191,067         N/A         2,667,182         50,102,750   

Michael D. Casey

     311,233,768         N/A         5,624,481         50,102,750   

Carrie S. Cox

     312,426,586         N/A         4,431,663         50,102,750   

Rodman L. Drake

     311,280,070         N/A         5,578,179         50,102,750   

Michael A. Friedman, M.D.

     315,053,581         N/A         1,804,668         50,102,750   

Gilla Kaplan, Ph.D.

     310,446,077         N/A         6,412,172         50,102,750   

James J. Loughlin

     309,089,445         N/A         7,768,804         50,102,750   

Ernest Mario, Ph.D.

     284,204,034         N/A         32,654,215         50,102,750   

Proposal 2. Ratification of Appointment of KPMG LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2012:

 

For

     356,109,800   

Against

     10,314,324   

Abstain

     536,875   

Broker Non-Votes

     50,102,750   

 

2


Proposal 3. Amendment to the Company’s 2008 Stock Incentive Plan (the description of the amendment contained in Item 5.02 of this Current Report on Form 8-K is incorporated herein by reference):

 

For

     247,036,030   

Against

     69,208,231   

Abstain

     613,988   

Broker Non-Votes

     50,102,750   

Proposal 4. Advisory Vote on Executive Compensation:

 

For

     302,226,159   

Against

     14,187149   

Abstain

     444,941   

Broker Non-Votes

     50,102,750   

Proposal 5. Advisory Vote on Stockholder Proposal (described in more detail in the Proxy Statement):

 

For

     189,500,550   

Against

     126,638,690   

Abstain

     719,009   

Broker Non-Votes

     50,102,750   

(c) Not applicable.

(d) Not applicable.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

 

(d) Exhibits

 

10.1    Amendment No. 2 to the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of June 17, 2009)

 

3


SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CELGENE CORPORATION
Date: June 14, 2012     By:  

/s/ Jacqualyn A. Fouse

      Jacqualyn A. Fouse
      Executive Vice President and Chief Financial Officer

 

4


EXHIBIT INDEX

 

Exhibit
Number

  

Description

10.1    Amendment No. 2 to the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of June 17, 2009)